The Role of RP105 in Cardiovascular Disease through Regulating TLR4 and PI3K Signaling Pathways

Abstract

Raidoprotective 105 (RP105) was first discovered on the surface of mouse B cells and it has been demonstrated that RP105 can function as an inflammatory regulator in cardiovascular disease (CVD), such as myocardial ischemic reperfusion injury (MI/RI), atherosclerosis and myocardial infarction (MI). As a member of Toll-like receptor (TLR) homolog which is capable of regulating toll-like receptor (TLR4) signaling pathway, RP105 is implicated in various biological processes. Mounting evidence suggests that RP105 regulates the function of TLR4 and phosphoinositide 3-kinase (PI3K) signaling pathways. Here, we review the effect of RP105 on CVD through regulating TLR4/PI3K signaling pathways.

Keywords

RP105 / TLR4 signaling / PI3K signaling / cardiovascular disease

References

[1] MiyakeK, YamashitaY, OgataM, et al.. RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family. J Immunol, 1995, 154(7): 3333-3340

[2] KarperJC, de JagerSC, EwingMM, et al.. An Unexpected Intriguing Effect of Toll-Like Receptor Regulator RP105 (CD180) on Atherosclerosis Formation with Alterations on B-Cell Activation. Arteriosclerosis, Arterioscler Thromb Vasc Biol, 2013, 33(12): 2810-2817

[3] NagaiY, AkashiS, NagafukuM, et al.. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol, 2002, 3(7): 667-672

[4] DivanovicS, TrompetteA, PetiniotLK, et al.. Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105. J Leukoc Biol, 2007, 82(2): 265-271

[5] HaT, HuaF, LiuX, et al.. Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. Cardiovasc Res, 2008, 78(3): 546-553

[6] DivanovicS, TrompetteA, AtabaniSF, et al.. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol, 2005, 6(6): 571-578

[7] AkashiS, ShimazuR, OgataH, et al.. Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol, 2000, 164(7): 3471-3475

[8] HoeferIE, van RoyenN, RectenwaldJE, et al.. Direct evidence for tumor necrosis factor-α signaling in arteriogenesis. Circulation, 2002, 105(14): 1639-1641

[9] YangJ, GuoX, YangJ, et al.. RP105 Protects against Apoptosis in Ischemia/Reperfusion-Induced Myocardial Damage in Rats by Suppressing TLR4-Mediated Signaling Pathways. Cell Physiol Biochem, 2015, 36(6): 2137-2148

[10] HreniukD, GarayM, GaardeW, et al.. Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes. Mol Pharmacol, 2001, 59(4): 867-874

[11] YangZ, DengY, SuD, et al.. TLR4 as receptor for HMGB1-mediated acute lung injury after liver ischemia/reperfusion injury. Lab Invest, 2013, 93(7): 792-800

[12] YangCJ, YangJ, YangJ, et al.. Radioprotective 105 kDa protein (RP105): is a critical therapeutic target for alleviating ischemia reperfusion induced myocardial damage via TLR4 signaling pathway. Int J Cardiol, 2016, 222: 1069-1070

[13] WatanabeY, NagaiY, TakatsuK. Activation and regulation of the pattern recognition receptors in obesity-induced adipose tissue inflammation and insulin resistance. Nutrients, 2013, 5(9): 3757-3778

[14] YangJ, YangJ, DingJW, et al.. Sequential expression of TLR4 and its effects on the myocardium of rats with myocardial ischemia-reperfusion injury. Inflammation, 2008, 31(5): 304-312

[15] JianJ, XuanF, QinF, et al.. Bauhinia championii flavone inhibits apoptosis and autophagy via the PI3K/Akt pathway in myocardial ischemia/reperfusion injury in rats. Drug Des Devel Ther, 2015, 9: 5933-5945

[16] BastiaansenAJ, EwingMM, de BoerHC, et al.. Lysine acetyltransferase PCAF is a key regulator of arteriogenesis. Arterioscler Thromb Vasc Biol, 2013, 33(8): 1902-1910

[17] HillisLD, LangeRA. Myocardial infarction and the open-artery hypothesis. N Engl J Med, 2006, 355(23): 2475

[18] AkiraS, TakedaK, KaishoT. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol, 2001, 2(8): 675-680

[19] YangZ, DengY, SuD, et al.. TLR4 as receptor for HMGB1-mediated acute lung injury after liver ischemia/reperfusion injury. Lab Invest, 2013, 93(7): 792-800

[20] DingHS, YangJ, ChenP, et al.. The HMGB1-TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis. Gene, 2013, 527(1): 389-393

[21] YangJ, ChenL, YangJ, et al.. MicroRNA-22 targeting CBP protects against myocardial ischemia-reperfusion injury through anti-apoptosis in rats. Mol Biol Rep, 2014, 41(1): 555-561

[22] WezelA, de VriesMR, MaassenJM, et al.. Deficiency of the TLR4 analogue RP105 aggravates vein graft disease by inducing a pro-inflammatory response. Sci Rep, 2016, 6: 24248

[23] LibbyP, RidkerPM, HanssonGK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol, 2009, 54(23): 2129-2138

[24] WoollardKJ. Immunological aspects of atherosclerosis. Clin Sci, 2013, 125(5): 221-235

[25] WeberC, NoelsH. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med, 2011, 17(11): 1410-1422

[26] HanssonGK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 2005, 352(16): 1685-1695

[27] HanssonGK, HermanssonA. The immune system in atherosclerosis. Nat Immunol, 2011, 12(3): 204-212

[28] MichelsenKS, WongMH, ShahPK, et al.. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A, 2004, 101(29): 10679-10684

[29] DingY, SubramanianS, MontesVN, et al.. Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol, 2012, 32(7): 1596-1604

[30] LuZ, ZhangX, LiY, et al.. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice. J Endocrinol, 2013, 216(1): 61-71

[31] AllenJL, FlickLM, DivanovicS, et al.. Cutting edge: regulation of TLR4-driven B cell proliferation by RP105 is not B cell autonomous. J Immunol, 2012, 188(5): 2065-2069

[32] GruberS, HendrikxT, TsiantoulasD, et al.. Sialic Acid-Binding Immunoglobulin-like Lectin G Promotes Atherosclerosis and Liver Inflammation by Suppressing the Protective Functions of B-1 Cells. Cell Rep, 2016, 14(10): 2348-2361

[33] WezelA, VeldenD, MaassenJM, et al.. RP105 deficiency attenuates early atherosclerosis via decreased monocyte influx in a CCR2 dependent manner. Atherosclerosis, 2015, 238(1): 132-139

[34] LewisEF, MoyeLA, RouleauJL, et al.. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol, 2003, 42(8): 1446-1453

[35] TimmersL, SluijterJP, van KeulenJK, et al.. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res, 2008, 102(2): 257-264

[36] FrantzS, KobzikL, KimYD, et al.. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest, 1999, 104(3): 271-280

[37] ArslanF, SmeetsMB, Riem VisPW, et al.. Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ Res, 2011, 108(5): 582-592

[38] LouweMC, KarperJC, de VriesMR, et al.. RP105 deficiency aggravates cardiac dysfunction after myocardial infarction in mice. Int J Cardiol, 2014, 176(3): 788-793